{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"494"},{"groupId":"OG001","value":"485"}]}],"title":"Any adverse event (AE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"151"}]}],"title":"Serious adverse events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"69"}]}],"title":"Leading to discontinuation of study drug"},{"categories":[{"measurements":[{"groupId":"OG000","value":"459"},{"groupId":"OG001","value":"437"}]}],"title":"Any treatment-related adverse event (TRAE)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}]}],"title":"Treatment-related serious adverse event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"}]}],"title":"TRAE leading to discontinuation of study drug"}],"denoms":[{"counts":[{"groupId":"OG000","value":"503"},{"groupId":"OG001","value":"496"}],"units":"Participants"}],"description":"Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs are those the investigator considered as a reasonable possibility to have been caused by study drug.","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set (randomized participants who received at least 1 dose of study medication). Five participants who received the incorrect study medication (4 assigned to panitumumab but received cetuximab and 1 assigned to cetuximab but received panitumumab) were included in different treatment arms for safety analyses.","reportingStatus":"POSTED","timeFrame":"From the day of the first dose of study therapy through 30 days since the last dose. Maximum time on study treatment was 130 weeks.","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"participants"}